The biotech company said it was testing the drug Jakafi to treat COVID-19 associated cytokine storm, where the immune system overreacts to the viral infection resulting in complications like pneumonia or acute respiratory distress syndrome.Based on the strength of the data, a Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, in healthy volunteers, has now commenced in the United States and Belgium, the company said.